FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
Quarterly Report Under Section 13 or 15 (d)
of the Securities Exchange Act of 1934
For Quarter Ended June 30, 1999
Commission File Number 0-9387
Empi, Inc.
(Exact name of registrant as specified in its charter)
Minnesota 41-1310335
(State or other jurisdiction of (I.R.S. employer
incorporation or organization) identification no.)
599 Cardigan Road
St. Paul, Minnesota 55126-4099
(Address of principal (Zip code)
executive offices)
Registrant's telephone number, including area code (651) 415-9000
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes |X| No |_|
6,091,180 shares of common stock were outstanding as of July 23, 1999.
<PAGE>
EMPI, INC. & SUBSIDIARIES
INDEX PAGE
Part I. FINANCIAL INFORMATION
Item 1. Consolidated Financial Statements
Unaudited Consolidated Balance Sheets as of June 30,
1999 and December 31, 1998 3
Unaudited Consolidated Statements of Operations for
the periods ended June 30, 1999 and 1998 4
Unaudited Consolidated Statements of Cash Flows for
the periods ended June 30, 1999 and 1998 5
Notes to Unaudited Consolidated Financial Statements 6
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations 9
Part II. OTHER INFORMATION
Item 4. Submission of Matters to a Vote of Security Holders 14
Item 6. Exhibits and Reports on Form 8-K 15
<PAGE>
PART I - - FINANCIAL INFORMATION
Item 1. Consolidated Financial Statements
EMPI, INC. & SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands)
<TABLE>
<CAPTION>
June 30 December 31
1999 1998
---------------- -----------------
(Unaudited) (Audited)
<S> <C> <C>
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 1,646 $ 1,851
Accounts receivable, net of allowances 21,101 20,441
Inventories - Note B 8,100 8,023
Deferred income tax benefit 4,844 4,294
Other 551 805
------------ -----------
TOTAL CURRENT ASSETS 36,242 35,414
PROPERTY, PLANT AND EQUIPMENT - NET 4,850 5,087
OTHER ASSETS 541 799
----------- -----------
$ 41,633 $ 41,300
=========== ===========
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable $ 2,534 $ 1,720
Customer advances 297 351
Employee compensation 1,625 1,801
Commissions payable 534 585
Current portion of long-term debt 66 66
Income taxes payable -- 584
Other 402 405
----------- -----------
TOTAL CURRENT LIABILITIES 5,458 5,512
LONG-TERM DEBT, LESS CURRENT PORTION -- --
SHAREHOLDERS' EQUITY:
Common stock (30,179) (24,853)
Retained earnings 66,354 60,641
----------- -----------
TOTAL SHAREHOLDERS' EQUITY 36,175 35,788
----------- -----------
$ 41,633 $ 41,300
=========== ===========
</TABLE>
See notes to consolidated financial statements.
<PAGE>
FORM 10 - Q - - PART I - ITEM 1 (CONTINUED)
EMPI, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
<TABLE>
<CAPTION>
Three Months Ended Six Months Ended
June 30 June 30
1999 1998 1999 1998
-------------- --------------- --------------- --------------
(Unaudited) (Unaudited)
<S> <C> <C> <C> <C>
Net sales $ 19,048 $ 18,266 $ 36,329 $ 35,263
Cost of goods sold 4,909 4,715 9,266 8,970
-------------- --------------- --------------- --------------
GROSS PROFIT 14,139 13,551 27,063 26,293
Operating expenses:
Selling, general and administrative 8,148 8,372 16,066 16,475
Research and development 932 844 1,807 1,685
-------------- --------------- --------------- --------------
Total operating expenses 9,080 9,216 17,873 18,160
-------------- --------------- --------------- --------------
INCOME FROM OPERATIONS 5,059 4,335 9,190 8,133
Other income, net 14 200 24 533
-------------- --------------- --------------- --------------
EARNINGS BEFORE INCOME TAXES
5,073 4,535 9,214 8,666
Income tax expense 1,927 1,747 3,501 3,337
-------------- --------------- --------------- --------------
NET EARNINGS $ 3,146 $ 2,788 $ 5,713 $ 5,329
============== =============== =============== ==============
BASIC EARNINGS PER SHARE $ .51 $ .39 $ .92 $ .71
============== =============== =============== ==============
Weighted average shares
outstanding - Note C 6,166 7,115 6,218 7,466
DILUTED EARNINGS PER SHARE $ .50 $ .39 $ .90 $ .71
============== =============== =============== ==============
Diluted weighted average shares
outstanding -Note C 6,255 7,190 6,314 7,557
</TABLE>
See notes to consolidated financial statements.
<PAGE>
FORM 10 - Q - - PART I - ITEM 1 (CONTINUED)
EMPI, INC. & SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
<TABLE>
<CAPTION>
Six Months Ended
June 30
1999 1998
----------------- ---------------
(Unaudited)
<S> <C> <C>
OPERATING ACTIVITIES
Net earnings $ 5,713 $ 5,329
Adjustments to reconcile net earnings to net cash
provided by (used in) operating activities:
Depreciation and amortization 1,164 1,704
Provision for deferred income taxes (550) 127
Provisions for loss on accounts receivable 1,382 1,099
Changes in operating assets and liabilities:
Accounts receivable (2,042) (702)
Inventories (77) (271)
Accounts payable and accrued expenses 533 (131)
Income taxes payable (465) 1,083
Other assets and liabilities 294 (9)
-------------- -------------
NET CASH PROVIDED BY OPERATING ACTIVITIES 5,952 8,229
INVESTING ACTIVITIES
Maturities of short-term investments -- 21,880
Purchase of short-term investments -- (5,450)
Additions of other assets (15) (1)
Purchase of equipment and improvements (660) (278)
-------------- -------------
NET CASH PROVIDED BY(USED IN) INVESTING ACTIVITIES (675) 16,151
FINANCING ACTIVITIES
Purchases and retirement of common stock (5,856) (25,277)
Proceeds from exercise of common stock options 374 222
-------------- --------------
NET CASH USED IN FINANCING ACTIVITIES (5,482) (25,055)
-------------- --------------
NET INCREASE IN CASH AND CASH EQUIVALENTS (205) (675)
Cash and cash equivalents at beginning of year 1,851 3,020
-------------- -------------
CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 1,646 $ 2,345
============== =============
</TABLE>
See notes to consolidated financial statements.
<PAGE>
FORM 10 - Q - - PART I - ITEM 1 (CONTINUED)
EMPI, INC. & SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE A - ACCOUNTING POLICIES
The accompanying unaudited consolidated financial statements have been prepared
in accordance with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-Q and Article 10 of
Regulation S-X. Accordingly, they do not include all of the information and
footnotes required by generally accepted accounting principles for complete
financial statements. In the opinion of management of the Company, all
adjustments (consisting of only normal recurring accruals) considered necessary
for a fair presentation of the results have been included. Operating results for
the six months ended June 30, 1999 are not necessarily indicative of the results
that may be expected for the year ended December 31, 1999. For further
information, refer to the consolidated financial statements and footnotes
thereto included in Empi, Inc. and Subsidiaries' annual report on Form 10-K for
the year ended December 31, 1998.
NOTE B - INVENTORIES
(In thousands)
June 30 December 31
1999 1998
------------ -----------
(Unaudited) (Audited)
Finished goods $ 5,087 $ 5,670
Work in process 848 651
Raw materials and purchased parts 2,165 1,702
----------- -----------
$ 8,100 $ 8,023
=========== ===========
<PAGE>
FORM 10 - Q - - PART I - ITEM 1 (CONTINUED)
NOTE C - EARNINGS PER SHARE
The following table sets forth the computation of basic and diluted earnings per
share:
<TABLE>
<CAPTION>
Three Months Ended Six Months Ended
June 30 June 30
1999 1998 1999 1998
------ ------ ------ ------
(In thousands, except per share data)
<S> <C> <C> <C> <C>
Net earnings $3,146 $2,788 $5,713 $5,329
Denominator for earnings per share:
Weighted average shares; denominator
for basic earnings per share 6,166 7,115 6,218 7,466
Effect of dilutive securities:
Employee and nonemployee stock options 89 75 96 91
------ ------ ------ ------
Dilutive common shares; denominator
for diluted earnings per share 6,255 7,190 6,314 7,557
====== ====== ====== ======
Basic earnings per share $ .51 $ .39 $ .92 $ .71
====== ====== ====== ======
Diluted earnings per share $ .50 $ .39 $ .90 $ .71
====== ====== ====== ======
</TABLE>
NOTE D - SEGMENT INFORMATION
The Company adopted Statement of Financial Accounting Standards No. 131,
"Disclosures about Segments of an Enterprise and Related Information" ("SFAS
131") in the fiscal year ended December 31, 1998. SFAS 131 establishes standards
for reporting information regarding operating segments in annual financial
statements and requires selected information for those segments to be presented
in interim financial reports issued to stockholders. SFAS 131 also establishes
standards for related disclosures about products and services and geographic
areas. Operating segments are identified as components of an enterprise about
which separate discrete financial information is available for evaluation by the
chief operating decision maker, or decision making group, in making decisions
how to allocate resources and assess performance. To date, the Company has
viewed its operations as principally one segment, the sale of non-invasive
biomedical devices and accessories. As a result, the financial information
disclosed herein, materially represents all of the financial information related
to the Company's principal operating segment.
<PAGE>
FORM 10 - Q - - PART I - ITEM 1 (CONTINUED)
NOTE D - SEGMENT INFORMATION, CONTINUED
Net sales from the Company's product lines are as follows:
<TABLE>
<CAPTION>
Three Months Ended Six Months Ended
June 30, June 30,
1999 1998 1999 1998
------------------------- -------------------------
(In thousands)
<S> <C> <C> <C> <C>
Electrotherapy $11,829 $11,491 $22,850 $22,037
Iontophoresis and Orthotics 7,040 6,546 13,147 12,736
Incontinence 179 229 332 490
========================= =========================
Total net sales
$19,048 $18,266 $36,329 $35,263
========================= =========================
</TABLE>
NOTE E - DEFINITIVE MERGER AGREEMENT
On May 27, 1999, the Company signed a definitive merger agreement with an
affiliate of The Carlyle Group for the acquisition of Empi. Pursuant to the
agreement, all of the Company's outstanding Common Stock and the Common Stock
underlying all unexercised stock options would be acquired by the affiliate of
The Carlyle Group for $26.50 per share. Consummation of the merger is subject to
satisfaction of various conditions, including approval of the transaction by the
shareholders of Empi. A shareholder meeting to vote on the merger is expected to
occur during third quarter of 1999 and, if approved, closing of the transaction
will occur shortly thereafter.
<PAGE>
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations.
Results of Operations
Sales
Empi, Inc.'s ("Empi" or the "Company") net sales for second quarter 1999 totaled
$19.0 million compared to 1998 second quarter sales of $18.3 million, an
increase of 4%. This percentage increase in net sales was primarily a result of
an increase in volume. Electrotherapy sales accounted for 62% and 63% of total
sales for the second quarters of 1999 and 1998, respectively. The electrotherapy
product group experienced a 3% increase in net sales compared to the same period
last year due to increased volume. For second quarter, the Company experienced a
7% increase within the iontophoretic drug delivery product group. The orthotics
product group increased 8%, which was led by steadily increasing sales of the
Protonics(TM) orthoses. Over the same period in prior year, the incontinence
product line decreased 22% from an already small base. International sales for
the second quarter of 1999, as a percentage of total sales, increased to 5% from
3% for the same period last year. International sales continue to be adversely
impacted by the strength of the U.S. dollar.
For the first six months of 1999, net sales were $36.3 million compared to $35.3
million in the first six months of 1998, an increase of 3%. This increase was
primarily attributable to electrotherapy sales which grew 4% in the first six
months of 1999 compared to the year-earlier period. The Company experienced a 2%
increase, 7% increase and 32% decrease in iontophoretic, orthotic and
incontinence sales, respectively, for the first six months of 1999 compared to
the same period of the prior year. The year-to-date increase in iontophoretic
product group sales was due to the strong sales of Dupel electrodes. The
increase in the orthotic product group was due to stronger sales of the Advance
Dynamic ROM(R) and Protonics product lines. Consistent with the second quarter
of 1999, year-to-date sales of the incontinence product group were negatively
impacted by the lack of Medicare reimbursement.
Empi continues to encounter pricing pressures from third-party payors and price
volume concessions within preferred supplier agreements primarily for its
electrotherapy products. However, the Company's overall average net selling
prices for these products have improved in 1999 due, in part, to the 1998
introduction of Epix VT(R), a high-end TENS device that provides greater
functionality. Lack of Medicare reimbursement for pelvic floor stimulation
continues to adversely impact the growth of the Company's incontinence product
line, and management does not anticipate that this situation will change in the
near future. However, the Company continues to have discussions with the Health
Care Financing Administration ("HCFA") for a favorable national reimbursement
decision relative to its incontinence treatment products. A HCFA review is
scheduled for late 1999.
Gross Profit
Gross profit for the second quarter of 1999 was $14.1 million compared to $13.6
million in the 1998 second quarter, an increase of 4%. Year-to-date, gross
profit increased 3% compared to the same period in 1998. As a percentage of net
sales, gross profit was 74% in the second quarter of
<PAGE>
FORM 10 - Q - - PART I - ITEM 2 (Continued)
Gross Profit - Continued
1999 and 1998 and 75% for the first six months of 1999 and 1998 as a result of
manufacturing efficiencies and increased retail electrotherapy sales.
The Company anticipates that throughout 1999, gross profit, as a percentage of
net sales, will remain near its current level or experience a slight decrease.
Factors that continue to influence the Company's gross profit margin include:
competitive pricing and reimbursement pressures, shifts in product mix,
proportion of wholesale to retail sales, and continued efficiencies achieved in
manufacturing and distribution.
Selling, General and Administrative
Selling, general and administrative ("SG&A") expenses for second quarter were
$8.1 million, or 43% of net sales, and $8.4 million, or 46% of net sales, in
1999 and 1998, respectively. For the six months ended June 30, 1999, SG&A
expenses were $16.1 million, or 44% of net sales compared to $16.5 million, or
47% of net sales, for the six months ended June 30, 1998. The primary
contributor to the decrease in SG&A expenses from the prior year was reduced
amortization expense related to previous acquisitions.
The Company plans for no significant increases or decreases in selling, general
and administrative expenses for 1999.
Research and Development
Research and development expenses increased 10% to $932,000 in the second
quarter of 1999 compared to $844,000 in the second quarter of 1998.
Year-to-date, research and development expenses increased to $1.8 million in
1999 from $1.7 million in 1998, a 7% increase. The increase is primarily from
clinical and consulting expenses. Stated as a percentage of net sales, research
and development costs remained consistent at 5% for the second quarters and
first six months of 1999 and 1998.
Research and development spending continues to be driven by activities related
to developing new products, continuation engineering and next-generation
products. Empi's products are regulated under the federal Food, Drug and
Cosmetic Act requiring clearance from the U.S. Food and Drug Administration
(FDA) prior to market introduction. The Company's long-term growth is dependent
upon continued FDA clearance, which may be delayed or denied, thus affecting
positively or negatively the successful introduction of new products or new
applications of existing technology.
<PAGE>
FORM 10 - Q - - PART I - ITEM 2 (Continued)
Other Income and Expenses
Interest income for the second quarter and first six months of 1999 was $24,000
and $71,000, respectively, compared to $181,000 and $434,000 in the same periods
of 1998. Interest income decreased substantially as a result of the reduced cash
position from the stock repurchasing activity. In addition, the first six months
of 1998 included income received from an insurance settlement.
Net Earnings
Net earnings were $3.1 million and $5.7 million for the second quarter and first
six months of 1999, respectively, compared to $2.8 million and $5.3 million for
the same periods last year, an increase of 13% and 7%. An increase in gross
margin of 4% and an overall decrease in operating expenses of 1% offset by
reduced interest income were the primary reasons for the improvement in net
earnings for second quarter. The year-to-date increase was attributed to a 3%
increase in gross margin and 2% decrease in operating expenses offset by reduced
interest income. Diluted earnings per share increased from $.39 per share in
second quarter 1998 to $.50 in second quarter 1999 and from $.71 per share in
the first six months of 1998 to $.90 for the first six months of 1999. The
Company's stock repurchase program contributed $.03 per share to the second
quarter $.11 diluted earnings per share increase.
To achieve continued net earnings growth in 1999, the Company must experience
both a growth in gross margin and continued management of expenses.
Liquidity and Capital Requirements
The Company's cash and cash equivalents were approximately $1.6 million at June
30, 1999, compared to $1.9 million at the end of December 1998. The decrease in
cash and cash equivalents is primarily a result of the stock repurchases during
1998 and the first six months of 1999. Since January 1, 1999, the Company has
repurchased 251,610 shares of common stock for approximately $5.9 million. Of
this total, 86,000 shares for $1.9 million were repurchased during second
quarter of 1999. Due to the contemplated merger agreement with The Carlyle
Group, the Company will not continue its stock repurchase program. Empi's
working capital as of June 30, 1999 was $30.8 million, an increase of $900,000
compared to $29.9 million at December 31, 1998. The current ratio was 6.6 to 1
at the end of second quarter 1999 compared with 6.4 to 1 at December 31, 1998.
The Company believes its existing cash together with internally generated funds
and its $10 million uncommitted line of credit will be sufficient to meet its
working capital and other cash requirements for the immediate and foreseeable
future.
<PAGE>
FORM 10 - Q - - PART I - ITEM 2 (Continued)
Year 2000
The Year 2000 ("Y2K") century date issue affects software, hardware and
databases from nearly every source. Historically, most computer systems were
designed to represent century dates with two digits rather than four. As a
result, if these systems recognize "00" as the year 1900 rather than the year
2000, the systems could fail or create erroneous results. Incomplete or untimely
resolution of the Y2K issue by the Company, its key suppliers, customers and
other parties could have a material adverse effect on the Company's results of
operations, financial condition and cash flows. To address the Y2K issue, Empi
has established a Year 2000 Project team led by the Chief Financial Officer,
with participation from the Director of Information Systems and other business
department representatives.
The Company's Y2K Project has been divided into three major phases: Inventory
and Assessment of Business Systems, Remediation and Replacement, and Testing.
Inventory and Assessment of Business Systems
This phase commenced in August of 1998 and was designed to identify internal and
external business systems that are susceptible to failure or miscalculation due
to the Y2K issue. The Company has completed the inventory and assessment of its
critical information technology ("IT") business systems. The Company has also
completed the inventory and assessment of its non-critical IT and
non-information technology ("non-IT") systems. Non-IT systems include, but are
not limited to, manufacturing production lines, elevators, heating and air
conditioning systems.
As part of this phase, Empi sent questionnaires to over 3,000 suppliers and
service providers requesting representation as to their Y2K readiness. The
Company has identified 200 of these vendors as critical to its business
operations. The Company submitted similar questionnaires to significant
customers, including managed health care organizations and governmental
entities, during first quarter of 1999. The readiness of its key suppliers and
customers will continue to be monitored by Empi throughout 1999.
Remediation and Replacement
The Company commenced remediation and replacement efforts in early 1999.
Remediation and replacement has been completed on all affected critical internal
IT business systems. A completion date of December 1999 is expected for all
non-critical IT and non-IT systems. Given the Company's initial assessment, the
estimated total cost of remediation and replacement will approximate $500,000.
To date, the Company has spent approximately $300,000 of which a substantial
amount has been capitalized. The remaining costs are expected to be funded
through internally generated cash flow.
<PAGE>
FORM 10 - Q - - PART I - ITEM 2 (Continued)
Testing
Testing of the remediation and replacement of all internal and external affected
systems is expected to occur throughout 1999. Testing of all critical IT
business systems was completed during second quarter of 1999, and testing of
non-critical IT and non-IT systems is expected to be completed by December 1999.
Empi's company-wide efforts involved with its Year 2000 Project are being
designed to minimize the adverse effects of significant disruptions. There is no
assurance that the Company's Y2K readiness efforts will prevent a material
adverse impact on the results of its operations, financial condition and cash
flows since its compliance is dependent upon third parties also being Y2K ready
in a timely manner. Noncompliance by the Company or these third parties could
result in, among other things, delays in billing and cash collection, delays in
the receipt of supplies, and delays in delivery of finished product. Contingency
plans are being developed by the Company to mitigate, to the extent possible,
potential disruptions. The Company believes that if unforeseen delays were to
occur within the manufacturing process, consigned inventory of certain key
products would be sufficient to meet customers' immediate needs.
Cautionary Statements
Management's Discussion and Analysis contains certain forward-looking statements
related primarily to reimbursement for pelvic floor stimulation devices; gross
profit remaining at current levels or decreasing; holding selling, general and
administrative expenses at current levels; the contemplated sale of the Company
to The Carlyle Group; and Year 2000 issues, potential resolutions and costs.
These statements are subject to certain risks and uncertainties, which could
cause results to differ materially from those projected. These risks and
uncertainties, in addition to those discussed in Management's Discussion and
Analysis, include (i) shifts in product mix and proportion of wholesale to
retail sales; (ii) competitive pricing pressures and manufacturing and
distribution efficiencies; (iii) shareholder approval of the merger of the
Company with The Carlyle Group; and (iv) the accuracy and reliability of the
Company's, its suppliers' and its customers' assessment and remediation of Year
2000 issues.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Not applicable.
<PAGE>
PART II - - OTHER INFORMATION
Item 4. Submission of Matters to a Vote of Security Holders
The Company held its Annual Meeting of Shareholders on Wednesday,
April 28, 1999.
Proxies for the Annual Meeting were solicited pursuant to
Regulation 14 under the Securities Exchange Act of 1934. There was
no solicitation in opposition to management's nominees as listed
in the Company's Proxy Statement, and all nominees were elected.
By a vote of 5,346,503 shares in favor, 79,655 shares opposed and
11,761 shares abstaining, with no shares represented by broker
non-votes, the shareholders set the number of directors to be
elected at seven (7).
By the votes indicated, the following people were elected as Class
One Directors of the Company with terms expiring in 2002:
Number of Number of
Nominee Votes For Votes Withheld
-------------------------------------------------------------
Kenneth F. Tempero 5,157,207 280,712
H. Philip Vierling 5,157,478 280,441
The following is a list of the Directors of the Company with
continuing terms:
Directors with Continuing Terms Term Ending
-------------------------------------------------------------
Scott R. Anderson 2000
Bradley J. Beard 2001
Everett F. Carter 2001
Nazie M. Eftekhari 2000
Joseph E. Laptewicz, Jr. 2000
By a vote of 4,906,375 shares in favor, 459,846 shares opposed and
71,698 shares abstaining, with no shares represented by broker
non-votes, the shareholders approved an amendment to the Company's
1997 Stock Option Plan to increase the annual formula grants to
outside directors.
By a vote of 5,417,974 shares in favor, 13,971 shares opposed and
5,974 shares abstaining, with no shares represented by broker
non-votes, the shareholders approved the appointment of Ernst &
Young LLP as the Company's independent auditors for the year ended
December 31, 1999.
Please refer to the Company's Proxy Statement for the Annual
Meeting of Shareholders for further details.
<PAGE>
FORM 10 - Q - - PART II (Continued)
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits
Exhibit No. Description
(27) Financial Data Schedule
(filed only in electronic format)
(b) On June 4, 1999, the Company filed Form 8-K to report that a
definitive merger agreement was signed on May 27, 1999, by the
Company and an affiliate of The Carlyle Group. Pursuant to the
agreement, all of the Company's outstanding Common Stock and the
Common Stock underlying all unexercised stock options would be
acquired by the affiliate of The Carlyle Group for $26.50 per
share.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereto duly authorized.
Empi, Inc.
July 29, 1999 By /s/ Joseph E. Laptewicz, Jr.
Joseph E. Laptewicz, Jr.
Chief Executive Officer and Chairman of
the Board (Principal Executive Officer)
July 29, 1999 By /s/ Patrick D. Spangler
Patrick D. Spangler
Vice President, Chief Financial Officer
and Assistant Secretary (Principal
Financial and Accounting Officer)
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM SECOND
QUARTER 1999 FINANCIAL STATEMENTS AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<CURRENCY> U.S. Dollars
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> DEC-31-1999
<PERIOD-START> JAN-01-1999
<PERIOD-END> JUN-30-1999
<EXCHANGE-RATE> 1
<CASH> 1,646
<SECURITIES> 0
<RECEIVABLES> 21,101
<ALLOWANCES> 0
<INVENTORY> 8,100
<CURRENT-ASSETS> 36,242
<PP&E> 4,850
<DEPRECIATION> 0
<TOTAL-ASSETS> 41,633
<CURRENT-LIABILITIES> 5,458
<BONDS> 0
0
0
<COMMON> (30,179)
<OTHER-SE> 66,354
<TOTAL-LIABILITY-AND-EQUITY> 36,175
<SALES> 36,329
<TOTAL-REVENUES> 36,329
<CGS> 9,266
<TOTAL-COSTS> 9,266
<OTHER-EXPENSES> 17,873
<LOSS-PROVISION> 1,382
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> 9,214
<INCOME-TAX> 3,501
<INCOME-CONTINUING> 5,713
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 5,713
<EPS-BASIC> .92
<EPS-DILUTED> .90
</TABLE>
